BACKGROUND: The prescence of circulating tumor cells (CTCs) in the peripheral blood of cancer patients and their frequency has been correlated with disease status. METHODS: In this study, CTCs were characterized by flow cytometry and fluorescence microscopy after immunomagnetic enrichment from 7.5-ml blood samples collected from patients with prostate cancer in evacuated blood-draw tubes that contained an anticoagulant and a preservative. Events were classified as tumor cell candidates if they expressed cytokeratin, lacked CD45, and stained with the nucleic acid dye 4,6-diamidino-2-phenylindole. RESULTS: In the blood of prostate cancer patients, only few of these events were intact cells. Other CTC events appeared as damaged cells or cell fragments by microscopy. By flow cytometry, these events stained variably with 4,6-diamidino-2-phenylindole and frequently expressed the apoptosis-induced, caspase-cleaved cytokeratin 18. Similar patterns of cell disintegration were observed when cells of the prostate line LNCaP were exposed to paclitaxel before spiking the cells into normal blood samples. CONCLUSIONS: The different observed stages of tumor cell degradation or apoptosis varied greatly between patients and were not found in blood of normal donors. Enumeration of CTCs and identification of CTCs undergoing apoptosis may provide relevant information to evaluate the response to therapy in cancer patients. Copyright 2004 Wiley-Liss, Inc.
BACKGROUND: The prescence of circulating tumor cells (CTCs) in the peripheral blood of cancerpatients and their frequency has been correlated with disease status. METHODS: In this study, CTCs were characterized by flow cytometry and fluorescence microscopy after immunomagnetic enrichment from 7.5-ml blood samples collected from patients with prostate cancer in evacuated blood-draw tubes that contained an anticoagulant and a preservative. Events were classified as tumor cell candidates if they expressed cytokeratin, lacked CD45, and stained with the nucleic acid dye 4,6-diamidino-2-phenylindole. RESULTS: In the blood of prostate cancerpatients, only few of these events were intact cells. Other CTC events appeared as damaged cells or cell fragments by microscopy. By flow cytometry, these events stained variably with 4,6-diamidino-2-phenylindole and frequently expressed the apoptosis-induced, caspase-cleaved cytokeratin 18. Similar patterns of cell disintegration were observed when cells of the prostate line LNCaP were exposed to paclitaxel before spiking the cells into normal blood samples. CONCLUSIONS: The different observed stages of tumor cell degradation or apoptosis varied greatly between patients and were not found in blood of normal donors. Enumeration of CTCs and identification of CTCs undergoing apoptosis may provide relevant information to evaluate the response to therapy in cancerpatients. Copyright 2004 Wiley-Liss, Inc.
Authors: Andrew S McDaniel; Roberta Ferraldeschi; Rachel Krupa; Mark Landers; Ryon Graf; Jessica Louw; Adam Jendrisak; Natalee Bales; Dena Marrinucci; Zafeiris Zafeiriou; Penelope Flohr; Spyridon Sideris; Mateus Crespo; Ines Figueiredo; Joaquin Mateo; Johann S de Bono; Ryan Dittamore; Scott A Tomlins; Gerhardt Attard Journal: BJU Int Date: 2016-09-18 Impact factor: 5.588
Authors: Xiaosai Yao; Atish D Choudhury; Yvonne J Yamanaka; Viktor A Adalsteinsson; Todd M Gierahn; Christina A Williamson; Carla R Lamb; Mary-Ellen Taplin; Mari Nakabayashi; Matthew S Chabot; Tiantian Li; Gwo-Shu M Lee; Jesse S Boehm; Philip W Kantoff; William C Hahn; K Dane Wittrup; J Christopher Love Journal: Integr Biol (Camb) Date: 2014-02-13 Impact factor: 2.192
Authors: Malgorzata Banys; Andreas D Hartkopf; Natalia Krawczyk; Tatjana Kaiser; Franziska Meier-Stiegen; Tanja Fehm; Hans Neubauer Journal: Breast Cancer (Dove Med Press) Date: 2012-12-05